Page 3 - Thomas Eldered News Today

Roar BidCos outstanding public offer for Recipharm AB (publ) - Consent granted to correct error in the Convertible Bond Terms On 14 December 2020, EQT IX 1 2 ("Roar BidCo"), announced a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders of Convertible Bonds") in Recipharm AB (publ) ("Recipharm" or the "Company") to tender all their shares 3 and Convertible Bonds to Roar BidCo (the "Offer"). An offer document relating to th...

Electrolux Nomination Committees proposal for election of board members STOCKHOLM, Feb. 1, 2021 /PRNewswire/ — In preparation for the Electrolux Annual General Meeting on March 25, Electrolux Nomination Committee has decided to propose the re-election of all board members except Kai Wärn, who has declined re-election. Staffan Bohman is proposed to be re-elected as Chairman of the Board of Directors, and Petra Hedengran, Henrik Henriksson, Ulla Litzén, Karin Overbeck, Fredrik Person, Dav...

By Reuters Staff 1 Min Read STOCKHOLM (Reuters) - Buyout group EQT on Thursday raised its cash offer for contract pharmaceutical maker Recipharm, valuing the Swedish company at 24.9 billion Swedish crowns ($2.97 billion). EQT raised its bid to 232 crowns per share from the 220 crowns it had offered in December. “We consider this revised offer to be highly compelling for Recipharm’s shareholders,” EQT partner Erika Henriksson said in a statement. EQT added that the bid would not be increas...

路透新闻部 (Adds CEO quote, background) Dec 30 (Reuters) - Recipharm AB and Moderna Inc have finalized a deal under which the Sweden-based company will help manufacture Moderna’s COVID-19 vaccine outside the United States potentially starting early next year, the companies said on Wednesday. Recipharm last month said it had agreed to a preliminary deal with Moderna to fill and seal the packaging for the vaccine, which has recently been authorized for emergency use in the United States. T...

(2) Moderna, Inc. (NASDAQ:MRNA), biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization (CDMO), today announced that they have reached an agreement to support formulation and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The activity will be performed in Recipharms drug product manufacturing facility located in France. Subject to regulatory approva...

Article content Recipharm AB and Moderna Inc have finalized a deal under which the Sweden-based company will help manufacture Moderna’s COVID-19 vaccine outside the United States potentially starting early next year, the companies said on Wednesday. Recipharm last month said it had agreed to a preliminary deal with Moderna to fill and seal the packaging for the vaccine, which has recently been authorized for emergency use in the United States. We apologize, but this video has failed to load. ...

Offer document regarding Roar BidCo ABs cash offer to the shareholders and Holders of Convertible Bonds in Recipharm AB (publ) made public: EQT Tel: + 46 8 506 55 334, email: press@eqtpartners.com For administrative questions regarding the Offer, please contact your bank or the nominee registered as holder of your shares, or, in respect of the Convertible Bonds, Lucid Issuer Services Limited: Lucid Issuer Services Limited Attention: Owen Morris Email: recipharm@lucid-is.com The information in t...

By Reuters Staff 2 Min Read STOCKHOLM (Reuters) -Buyout group EQT on Monday announced a cash offer for Swedish contract pharmaceutical maker Recipharm, valuing the company at 23.6 billion Swedish crowns ($2.80 billion). Recipharm, a contract development and manufacturing organisation (CDMO) for the pharma industry, recently signed a preliminary deal with Moderna Inc to fill and seal the packaging for the U.S drugmaker’s new COVID-19 vaccine. EQT said it was bidding 220 crowns per Recipharm sh...

EQT Offers to Buy Recipharm of Sweden in $2.1 Billion Deal Bloomberg 12/14/2020 Charles Daly © Bloomberg Recipharm shares rose as much as 23% to 220.20 kronor, near the bid price, in Stockholm Monday morning. (Bloomberg) -- Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions. EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than F...